Бастиан Блоэм - Нестареющее тело. Научное исследование о том, как защитить свои тело и мозг и не допустить развития неврологических заболеваний

93. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme q10 in early Parkinson disease: evidence of slowing of the functional decline. Archives of Neurology. 2002;59(10): 1541–1550; Parkinson Study Group QE3 Investigators. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurology. 2014;71(5):543–552.

94. Adams CP, Brantner VV. Estimating the cost of new drug development: is it really $802 million? Health Affairs. 2006;25(2):420–428; Dorsey ER, Papapetropoulos S, Xiong M, Kieburtz K. The first frontier: digital biomarkers for neurodegenerative disorders. Digital Biomarkers. 2017;1(1):6-13; Dorsey ER, Venuto C, Venkataraman V, Harris DA, Kieburtz K. Novel methods and technologies for 21st-century clinical trials: a review. JAMA Neurology. 2015;72(5):582–588; CNS drugs take longer to develop and have lower success rates than other drugs [пресс-релиз]. Tufts Center for the Study of Drug Development. November 4, 2014. https://static1.squarespace.com/static/5a9eb0c8e2ccd1158288d8dc/tZ5aa 2bf604192023932fe1561/1520615264660/PR-NOVDEC14.pdf. Accessed June 28, 2019.

95. Dwyer C. Pfizer halts research into Alzheimer’s and Parkinson’s treatments. The Two-Way. January 8, 2018. www.npr.org/sections/ thetwo-way/2018/01/08/576443442/pfizer-halts-research-efforts-into-alzheimers-and-parkinsons-treatments. Accessed June 28, 2019.

96. Там же.

97. Taylor P. Backed by Bain, Pfizer loads prime CNS assets into new biotech. FierceBiotech. October 23, 2018. www.fiercebiotech.com/biotech/ embargo-8am-edt-backed-by-bain-pfizer-loads-prime-cns-assets-into-new-biotech. Accessed February 11, 2019.

98. Knabe K. Pfizer’s Parkinson’s drugs will be developed by start-up Cerevel Therapeutics. FoxFeed Blog. October 24, 2018. www.michaeljfox.org/ news/pfizers-parkinsons-drugs-will-be-developed-start-cerevel-therapeutics?fbclid=IwAR3Wb4f_I6J4AqORHZCpJZeYCzGAdymx 1jSxWVfuZCKTq_-UEWAvY_bHGhI&pfizer-parkinson-drugs-will-be-developed-by-start-up-cerevel-therapeutics=. Accessed June 28, 2019.

99. Lipsmeier F, Taylor KI, Kilchenmann T, et al. Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson’s disease clinical trial. Movement Disorders. 2018;33(8):1287–1297.

100. 221AD301 phase 3 study of aducanumab (BIIB037) in early Alzheimer’s disease (ENGAGE). US National Library of Medicine. Clinical Trials.gov. June 23, 2015. https://clinicaltrials.gov/ct2/show/study/NCT02477800. Updated August 6, 2018. Accessed March 28, 2019; Henriques C. MJFF partners with Verily to use data collection watch in PPMI study to advance Parkinson’s research. Parkinson’s News Today. May 14, 2018. https://parkinsonsnewstoday.com/2018/05/14/mjff-verily-collaborate-advance-parkinsons-research-using-study-watch-ppmi. Accessed March 28, 2019.

101. Little MA. A test for Parkinson’s with a phone call [видео]. TEDGlobal 2012. June 2012. www.ted.com/talks/max_little_a_test_for_parkinson_s_ with_a_phone_call. Accessed June 28, 2019.

102. den Brok MGHE, van Dalen JW, van Gool WA, Moll van Charante EP, de Bie RMA, Richard E. Apathy in Parkinson’s disease: a systematic review and meta-analysis. Movement Disorders. 2015;30(6):759–769; Patient advocates respond to the PD pandemic. WPC Blog. December 19, 2017. www.worldpdcongress.org/home/2017/12/15/patient-advocates-respond-to-the-pd-pandemic. Accessed June 28, 2019.

103. Gordon L. With Words as My Oars: Paddling the Parkinson’s Rapids. www.leonoregordonpdspeak.com. Accessed February 11, 2019; Wheatley Alumni Newsletter: Number 25: November 25, 2018. Wheatley School Alumni Association. November 25, 2018. www. wheatleyalumni.org/BlogPost/Blogpost-20181125-25.html. Accessed June 28, 2019.

104. Season 2: Mental Health. ParkinsonTV. July 2018. https://parkinsontv. org/two. Accessed February 11, 2019.

105. What are the odds of dying from. National Safety Council. 2017. www.nsc.org/work-safety/tools-resources/injury-facts/chart. Accessed February 11, 2019.

106. Driver JA, Logroscino G, Gaziano JM, Kurth T. Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology. 2009;72(5):432–438.

107. Mark Morris Dance Group. In memory of Leonore Gordon. Dance for PD. 2017. https://danceforparkinsons.org/photo-credits/permissions/ in-memory-of-leonore-gordon. Accessed February 11, 2019.

1. Bates C, Rowell A. Tobacco Explained: The Truth About the Tobacco Industry. Action on Smoking and Health; 1998.

2. Paraquat dichloride. US Environmental Protection Agency. www.epa. gov/ingredients-used-pesticide-products/paraquat-dichloride. Updated May 15, 2019. Accessed May 19, 2019; Paraquat Dichloride: One Sip Can Kill. US Environmental Protection Agency. Pesticide Worker Safety. https://www.epa.gov/pesticide-worker-safety/paraquat-dichloride-one-sip-can-kill. Last updated May 8, 2019. Accessed March 25, 2019.

3. Tanner CM, Kamel F, Ross GW, et al. Rotenone, paraquat, and Parkinson’s disease. Environmental Health Perspectives. 2011;119(6):866–872; Wang A, Costello S, Cockburn M, Zhang X, Bronstein J, Ritz B. Parkinson’s disease risk from ambient exposure to pesticides. European Journal of Epidemiology. 2011;26(7):547–555; Costello S, Cockburn M, Bronstein J, Zhang X, Ritz B. Parkinson’s disease and residential exposure to maneb and paraquat from agricultural applications in the Central Valley of California. American Journal of Epidemiology. 2009;169(8):919–926; McCormack AL, Thiruchelvam M, Manning-Bog AB, et al. Environmental risk factors and Parkinson’s disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiology of Disease. 2002;10(2):119–127.

4. Pesticide National Synthesis Project: estimated annual agricultural pesticide use. US Geological Survey. https://water.usgs.gov/nawqa/pnsp/ usage/maps/show_map.php?year= 2015&map=PARAQUAT&hilo=H. Updated September 11, 2018. Accessed March 25, 2019.

5. Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) and Federal Facilities. US Environmental Protection Agency. www.epa.gov/ enforcement/federal-insecticide-fungicide-and-rodenticide-act-fifra-and-federal-facilities. Updated January 29, 2018. Accessed March 29, 2019.

6. H.R.3817—To cancel the registration of all uses of the pesticide paraquat, and for other purposes. Congress.gov. www.congress.gov/bill/116th-congress/house-bill/3817/committees. Accessed July 19, 2019.

7. Freire C, Koifman S. Pesticide exposure and Parkinson’s disease: epidemiological evidence ofassociation. NeuroToxicology. 2012;33(5):947–971; Gatto NM, Cockburn M, Bronstein J, Manthripragada AD, Ritz B. Wellwater consumption and Parkinson’s disease in rural California. Environmental Health Perspectives. 2009;117(12):1912–1918; Chen T, Tan J, Wan Z, et al. Effects of commonly used pesticides in China on the mitochondria and ubiquitin-proteasome system in Parkinson’s disease. International Journal of Molecular Sciences. 2017;18(12):2507; Pallotta MM, Ronca R, Carotenuto R, et al. Specific effects of chronic dietary exposure to chlorpyrifos on brain gene expression-a mouse study. International Journal of Molecular Sciences. 2017;18(11):2467; Rauh VA. Polluting developing brains – EPA failure on chlorpyrifos. New England Journal of Medicine. 2018;378(13):1171–1174.

8. Pesticide tolerances: chlorpyrifos. Regulations.gov. www.regulations.gov/ document?D=EPA-HQ-OPP-2007-1005-0100. Accessed March 29, 2019.

9. Letters in support of September 2018 Department of Justice action on chlorpyrifos. US Environmental Protection Agency. www.epa.gov/ ingredients-used-pesticide-products/letters-support-september-2018-department-justice-action. Updated September 24, 2018. Accessed March 29, 2019.